Moderna Stock Doubles, Adding $26.4 Billion After Cancer Vaccine Meets Both Phase 3 Goals
Covered by 1 source · 1 article
Moderna stock more than doubled at its premarket peak Wednesday after the company’s personalized mRNA cancer treatment, developed with Merck, succeeded in a pivotal Phase 3 melanoma trial. MRNA rose by approximately 105% from Tuesday’s $62.…
Covered by
